Studies of Wegovy in higher-than-approved doses begin
![Photo: Jens Dresling/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/14927758/hh5tb9/ALTERNATES/schema-16_9/20200202-140932-A-5042x2830ma%2520(1).jpg)
This month, Novo Nordisk initiated two phase III trials of Wegovy (semaglutide), testing higher doses than the currently approved 2.4mg, revealed the Danish drugmaker’s annual report for 2022 on Wednesday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk doubles obesity sales in 2022
For subscribers
Novo Nordisk predicts wide range for 2023 sales growth
For subscribers